• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc (Amendment)

    2/12/24 8:20:06 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVDL alert in real time by email
    SC 13G/A 1 d10979828_13g-a.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    AVADEL PHARMACEUTICALS PLC
    (Name of Issuer)

     

     

    American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share
    (Title of Class of Securities)

     

     

    05337M104
    (CUSIP Number)

     

     

    February 12, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [ ] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No 05337M104    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Kevin Kotler  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      3,716,242  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      3,716,242  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,716,242 *  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.1%*  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN  

     

     

    * As of December 31, 2023, the Reporting Person beneficially owned 4,726,336 American Depositary Shares, constituting 5.3% of the American Depositary Shares outstanding as of such date.

     
     

     

     

    CUSIP No 05337M104    

     

    Item 1. (a). Name of Issuer:  
           
        AVADEL PHARMACEUTICALS PLC  

     

      (b). Address of Issuer's Principal Executive Offices:  
           
       

    10 Earlsfort Terrace

    Dublin 2 D02 T380

    Ireland

     

     

    Item 2. (a). Name of Person Filing:  
           
        Kevin Kotler  

     

      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Kevin Kotler

    c/o Broadfin Holdings LLC

    200 Broadhollow Road, Suite 207

    Melville, New York 11747

    United States of America

     

     

      (c). Citizenship:  
           
        Kevin Kotler – United States of America  

     

      (d).   Title of Class of Securities:  
           
        American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share  

     

      (e). CUSIP Number:  
           
        05337M104  

     

    Item 3.   If this Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

    (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
         
    (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
         
    (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
         
    (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
         
    (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
         
    (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
         
    (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
         
    (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).
     
     

     

     
    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
        Kevin Kotler – 3,716,242

     

      (b)   Percent of class:
         
        Kevin Kotler – 4.1%

     

      (c)   Number of shares as to which the person has:
         

     

        (i) Sole power to vote or to direct the vote Kevin Kotler – 3,716,242 ,
             
        (ii)   Shared power to vote or to direct the vote 0 ,
             
        (iii) Sole power to dispose or to direct the disposition of Kevin Kotler – 3,716,242 ,
             
        (iv)   Shared power to dispose or to direct the disposition of 0 .
             

     

      Instruction:  For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).
       
    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
       
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      N/A
     
     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 12, 2024
      (Date)
       
       
     

     

    By: /s/ Kevin Kotler

      (Signature)
       
       
       
      Kevin Kotler
      (Name/Title)
       
       
       
       

     

    * The Reporting Person disclaims beneficial ownership in the shares reported herein except to the extent of its pecuniary interest therein.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

    Get the next $AVDL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVDL

    DatePrice TargetRatingAnalyst
    7/18/2025$22.00Buy
    H.C. Wainwright
    2/11/2025$12.00Buy
    Deutsche Bank
    6/12/2024$27.00Buy
    Rodman & Renshaw
    3/5/2024$27.00 → $29.00Outperform
    Oppenheimer
    3/5/2024$21.00 → $25.00Buy
    H.C. Wainwright
    3/5/2024$20.00 → $22.00Buy
    Needham
    2/6/2024$21.00Buy
    UBS
    11/30/2022$6.50 → $11.00Hold → Buy
    Jefferies
    More analyst ratings

    $AVDL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

    DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference: Fireside chat on Friday, September 5 at 11:00 a.m. ET.Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside chat on Tuesday, September 9 at 1:05 p.m. ET.H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat on Wednesday, September 10 at 9:30 a.m. ET. A live webcast of these events, as well as archived recordings, will be available on Avadel's Invest

    8/29/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to eight (8) new employees to purchase 60,400 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the

    8/7/25 4:05:00 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

    -- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 -- -- Raises 2025 full year revenue guidance to $265 - $275 million -- -- Received Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ in IH by end of 2025 -- -- Avadel management to host conference call today at 8:30 a.m.

    8/7/25 7:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Avadel Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $22.00

    7/18/25 9:08:21 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deutsche Bank initiated coverage on Avadel Pharmaceuticals with a new price target

    Deutsche Bank initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    2/11/25 7:00:38 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Avadel Pharmaceuticals with a new price target

    Rodman & Renshaw initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $27.00

    6/12/24 7:06:25 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Avadel Pharmaceuticals plc

    SCHEDULE 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    8/14/25 11:00:36 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Avadel Pharmaceuticals plc

    S-8 - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

    8/7/25 4:28:29 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Avadel Pharmaceuticals plc

    S-3ASR - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

    8/7/25 4:06:53 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mccamish Mark Anthony was granted 11,000 units of Ordinary Shares, increasing direct ownership by 100% to 22,000 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    7/31/25 4:10:52 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Palczuk Linda was granted 11,000 units of Ordinary Shares, increasing direct ownership by 16% to 78,900 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    7/31/25 4:09:56 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thornton Peter J. was granted 11,000 units of Ordinary Shares, increasing direct ownership by 11% to 115,055 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    7/31/25 4:09:06 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Palczuk Linda bought $39,640 worth of Ordinary Shares (5,000 units at $7.93), increasing direct ownership by 8% to 67,900 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/22/25 4:13:34 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thornton Peter J. bought $80,450 worth of Ordinary Shares (10,000 units at $8.04), increasing direct ownership by 11% to 104,055 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/14/25 4:24:12 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ende Eric J bought $235,218 worth of Ordinary Shares (30,000 units at $7.84), increasing direct ownership by 17% to 208,900 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/14/25 4:22:57 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Leadership Updates

    Live Leadership Updates

    View All

    Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer

    DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer. In this newly created role, Ms. Rodriguez will lead all aspects of the Company's commercial strategy, structure, organization, and related operations, including supply chain. "Susan is an accomplished biopharma executive with a track record of strategic leadership and excellence in commercializing innovative medicines," said Gregory J. Divis, Chief Executive Officer of Avadel. "Her expertise will be invaluable at this critical

    5/13/25 4:15:00 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

    DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets. "We're delighted to welcome Kevin to Avadel – he's a great addition to our team with the deep experience to help us drive success at this important time," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Kevin's expertise and proven track record in build

    2/24/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement

    DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient support service teams across global healthcare and biopharmaceutical organizations. "We are thrilled to welcome Sev to the Avadel team," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Providing comprehensive support to patients and providers and continuously improvin

    1/22/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Financials

    Live finance-specific insights

    View All

    Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

    -- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 -- -- Raises 2025 full year revenue guidance to $265 - $275 million -- -- Received Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ in IH by end of 2025 -- -- Avadel management to host conference call today at 8:30 a.m.

    8/7/25 7:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7

    DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 7, 2025, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are

    7/31/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

    -- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate $255 - $265 million in net product revenue and cash flow of $30 - $40 million, driven by 3,400 - 3,600 patients on LUMRYZ by year end -- -- Federal Circuit ruled in Avadel's favor in appeal of Delaware Court injunction, allowing Avadel to seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in

    5/7/25 7:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/14/24 6:10:30 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/13/24 5:58:54 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/13/24 5:00:57 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care